Key Highlights

● The Health Care Select Sector SPDR fund hit record highs as money rotated into defensives.

● The PHLX Semiconductor Index fell to 11,137.29, with all 30 of its members lower.

● Memory makers also faced worries over Chinese rival CXMT's progress on advanced DRAM.

● Smaller drug developers and tools makers sold off while large health care names rose.

A tale of two sectors

Friday's market delivered one of its starkest contrasts in months. The Health Care Select Sector SPDR fund hit record highs as money rotated into defensive areas of the market. At the same time, the PHLX Semiconductor Index fell to 11,137.29 with all 30 of its members lower.

The broader market leaned toward the chip side of the ledger. The S&P 500 gave up 84.62 points to close at 7,659.44, and the Nasdaq Composite dropped 572.99 points to 26,140.03, capping its worst week since the week ended June 26.

Why chips crumbled

Semiconductor stocks were caught in a broader reassessment of the artificial intelligence trade. Investors shifted from asking what AI can do to how it will be financed, according to market commentary. Market reports said the rotation erased more than $1 trillion from semiconductor and AI-related stocks over the week.

Memory makers faced an extra worry: concerns about Chinese competition, specifically CXMT's progress on advanced DRAM. Micron Technology (NASDAQ:MU) slid, and Seagate Technology (NASDAQ:STX), Western Digital (NASDAQ:WDC) and Sandisk (NASDAQ:SNDK) tumbled. Advanced Micro Devices (NASDAQ:AMD), Intel (NASDAQ:INTC), Arm Holdings (NASDAQ:ARM) and Broadcom (NASDAQ:AVGO) also fell. Nvidia (NASDAQ:NVDA) wobbled, with reports mixed on its direction.

The losing streak has been unusually long. Some market reports counted an eighth straight decline for the sector, while others described it in even longer historical terms. Sources differed on the exact comparison.

Why health care held up

Large health care companies offered what chip stocks could not on Friday: steady demand and earnings that are less tied to the AI spending cycle. McKesson (NYSE:MCK), the drug distributor, set an intraday record high.

Company news also helped the sector this week. Eli Lilly (NYSE:LLY) received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use on Foundayo, its oral weight-loss drug orforglipron. UnitedHealth Group (NYSE:UNH) beat third-quarter estimates on Thursday, and both stocks rose for the week.

The rotation extended beyond health care. Energy, utilities and consumer staples were Friday's top sectors, and Visa (NYSE:V) and Mastercard (NYSE:MA) hit intraday records.

Not all of health care

The strength was concentrated in large, profitable companies. Smaller drug developers and life-sciences tools makers sold off as long-term Treasury yields stayed elevated. Novavax (NASDAQ:NVAX) plunged to about $11.20, PacBio (NASDAQ:PACB) sank to $1.74, and Azenta (NASDAQ:AZTA), Repligen (NASDAQ:RGEN) and QuidelOrtho (NASDAQ:QDEL) fell. Moderna (NASDAQ:MRNA) sank as investors trimmed positions ahead of Phase 3 data with Merck (NYSE:MRK) later this month. Omeros (NASDAQ:OMER) fell after the EMA's committee kept a negative opinion on narsoplimab.

BofA analysts pointed to near-full utilization of deployed AI infrastructure and said the risk is "priced in." One market commentator struck a more cautious tone: "That is a change in character, and it's another reason the leaders no longer look like a safe haven."

Health Care Earnings Meet Chip Reports

The Federal Reserve decides on rates on Oct 28. Health care earnings ramp up next week: Intuitive Surgical (NASDAQ:ISRG) reports after Tuesday's close, and Thermo Fisher (NYSE:TMO), Abbott (NYSE:ABT), Danaher (NYSE:DHR) and Elevance Health (NYSE:ELV) report Wednesday morning, with Molina (NYSE:MOH) after Wednesday's close. On the chip side, Lam Research (NASDAQ:LRCX) and Texas Instruments (NASDAQ:TXN) report Wednesday, Western Digital on Thursday and Intel on Oct 29.